←Epilepsy
Study register · detail Retrospektive Beobachtungsstudie · Epilepsy · 2016

CBD-enriched medical cannabis for intractable pediatric epilepsy

Tzadok et al. ·Seizure Impact 2.2
Clear benefit GRADE Very low 214 citations
Samplen = 74 Pat.
Durationat least 3 months
EndpointSeizure frequency
Blindingn.a.
DesignRetrospektive Beobachtungsstudie
Cannabinoidkombination
THC:CBD20:1
Routeoral
Key finding

CBD-rich cannabis oil reduced seizure frequency in 89% of treated children, by more than 50% in over half.

Summary

Retrospective multicenter study with n=74 children/adolescents (1-18 years) with treatment-refractory epilepsy (resistant to >7 antiepileptic drugs); CBD-enriched cannabis oil (CBD:THC=20:1, 1-20 mg/kg/d). 89% (66/74) reported seizure reduction: 18% >75% reduction, 34% 50-75% reduction, 12% 25-50% reduction. 5 (7%) patients seizure worsening → discontinuation. Treatment duration average 6 months.

P
PopulationChildren and adolescents (1-18 years) with treatment-refractory epilepsy (resistance to >7 antiepileptic drugs), n=74
I
InterventionCBD-enriched medical cannabis oil (CBD:THC 20:1 in olive oil), CBD dose 1-20 mg/kg/d, oral, average 6 months
O
Outcome89% of patients (66/74) reported a reduction in seizure frequency; 18% a reduction of 75-100%, 34% of 50-75%, 12% of 25-50%, 26% of <25%; 7% reported a worsening
Confidence in the evidence
Very low

The lowest GRADE level, the effect estimate remains uncertain.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Tzadok M, Uliel-Siboni S, Linder I et al.
DOI 10.1016/j.seizure.2016.01.004↗
Design: Retrospektive Beobachtungsstudie
Share
Indication
Further studies on Epilepsy
All studies →
S Devinsky et al. · 2018 · The New England journal of medicine
973 citations
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Clear benefit RCT

Multizentrische Phase-III-RCT bei Lennox-Gastaut-Syndrom (n=225, Alter 2-55 Jahre, 30 Zentren), Cannabidiol 20 mg/kg vs. 10 mg/kg vs. Placebo (14 Wochen). Baseline: median 85 Drop-Seizures/28 Tage. Mediane Reduktion der Drop-Seizure-Frequenz: 41,9% (20 mg/kg, p=0,005 vs. Placebo), 37,2% (10 mg/kg, p=0,002 vs. Placebo), 17,2% (Placebo). Häufigste Nebenwirkungen: Somnolenz, verminderter Appetit, Diarrhö (dosisabhängig); 6 Patienten (20 mg/kg-Gruppe) und 1 Patient (10 mg/kg-Gruppe) brachen wegen Nebenwirkungen ab.

10.1056/nejmoa1714631 View study →
S Devinsky et al. · 2017 · New England Journal of Medicine
1652 citations
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Clear benefit RCT

n=120 Dravet-Syndrom (therapierefraktär), CBD 20mg/kg/d vs. Placebo über 14 Wochen; median konvulsive Anfallsreduktion 38,9% (CBD) vs. 13,3% (Placebo), adjustierte Differenz -22,8 Prozentpunkte (95%-CI -41,1 bis -5,4; p=0,01); 5% anfallsfrei (CBD) vs. 0% (Placebo).

10.1056/nejmoa1611618 View study →
S Thiele et al. · 2018 · The Lancet
881 citations
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Clear benefit RCT

Phase-III-RCT (GWPCARE4) bei Lennox-Gastaut-Syndrom, n=171 (2–55 Jahre), randomisiert zu CBD 20 mg/kg/d vs. Placebo über 14 Wochen. Primärer Endpunkt: prozentuale Reduktion der monatlichen Drop-Seizure-Frequenz. Multizentrisch (24 Zentren USA, Niederlande, Polen). 14 Patienten in CBD-Gruppe, 1 in Placebo-Gruppe brachen ab. [Numerische Outcomes im Abstract abgeschnitten; Volltext zeigt signifikante Drop-Seizure-Reduktion vs. Placebo].

10.1016/s0140-6736(18)30136-3 View study →

The impediment to action advances action. — Marcus Aurelius